

September 25, 2024

**To,
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001**

Scrip Code: 500672

Dear Sir/ Madam,

Sub.: Intimation of event

Ref: Regulation 30 (read Part A of Schedule III) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')

Pursuant to Regulation 30 (read with Para A of Part A of Schedule III) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') and SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023 ('SEBI Circular'), as may be applicable, we would like to inform you that, Novartis India Limited has been importing DESFERAL® (deferoxamine) from Novartis Pharma AG and sell it in India. Mitem Pharma has decided to acquire DESFERAL® (deferoxamine) globally from Novartis Pharma AG.

This intimation is made pursuant to disclosure made by Mitem Pharma through a press release over BusinessWire on September 25, 2024, i.e. today.

The Company shall keep the Stock Exchange informed on any development or communication received in this regard.

The above is for your information.

Thanking you

Yours Sincerely,

For **Novartis India Limited**

Maru Chandni
Digitally signed by Maru Chandni
DN: dc=com, dc=novartis, ou=people, ou=LE,
serialNumber=3190945, cn=Maru Chandni
Date: 2024.09.25 20:54:10 +05'30'

Chandni Maru
Company Secretary and Compliance Officer